BioSpace News Archive

The data has been submitted to the EPA for review to include claims of disinfection against the virus on the label

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network (HPTN) 0

Boston Children’s Hospital is working with Boston Rocket League and Extra Life to host a Rocket League gaming tournament on July 11 and 12.

Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will, as expected, hold a virtual m

US Food & Drug Administration (FDA) clears Servo-air® mechanical ventilator for use with adult and pediatric patients dependent on intensive care ventilation expanding upon the Servo family of products available in the United States for decades. “FDA 510(k) clearance for Servo-air will broaden our US offering with a turbi

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield®, and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective June 22, 2020, it has entered into a two-year exclusive agreement with Ultra Pain Products, Inc.

Pear Therapeutics, Inc. (“Pear” or the “Company”) today announced that it closed a credit facility for up to $50 million from Perceptive Advisors (“Perceptive”), a leading life sciences investment firm. In connection with the financing, Pear issued warrants to Perceptive, and Sam Chawla of Perceptive received board observer rig

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, July 28, 2020 to discuss its second quarter 2020 financial results. The call may be accessed throug

Top-Line Results from First of Two Planned Clinical Trials Based on Tear RASP Levels Expected by the End of 2020 New Drug Application Submission for Reproxalap in Dry Eye Disease Expected by the End of 2021 Based on Current Operating Plans, Current Cash Expected to Support Operations into 2022, Consistent with Prior Guidance LEXINGTON, Mass.--( BUSINESS WIRE )-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-st

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on development of first-in-class drugs, announced today that encouraging preclinical results supporting newly-identified immunogenic effects of the company’s lead product candidate, investigational THIO (6-thio-dG), the